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1. Introduction  
 
Hypertrophic cardiomyopathy (HCM) is characterised by unexplained left ventricular 
hypertrophy in the absence of increased afterload. It is often a result of variants in 
sarcomeric genes including those that code for the actin and myosin filaments, the z 
discs and some calcium handling proteins. Mutations in MYBPC3, (affecting the 
myosin binding protein) MYH7 (affecting the myosin filament) TNNT2 and TNNI3 
(affecting the actin filament) have been reported as the most frequent. Non-
sarcomeric mutations are less common. 
 
Patients suspected of having HCM can undergo genetic testing. The benefits of 
testing lie predominantly in using details of a pathogenic mutation to assess risk in 
other family members, but some mutations can give useful prognostic information.  
 
We reviewed a consecutive series of HCM genetic panels performed across the 
Merseyside and Cheshire region in the UK and analysed for clinical parameters that 
predicted an informative result.  
 
2. Aims 
 
To identify clinical parameters that can predict an informative result in patients 
suspected of having HCM. 
 
 
3. Methods 
 
A retrospective analysis of 126 consecutive unrelated patients undergoing genetic 
testing with a confirmed diagnosis of HCM was conducted in a tertiary 
cardiomyopathy service between January 2014 and June 2016. We used a standard 
19-gene panel using next generation sequencing (Oxford molecular genetics 
laboratory, UK). Informative results included class 4 or 5 variants deemed 
‘pathogenic’ or ‘likely pathogenic’.  
 
Cardiac MRI and echocardiography were used to identify left ventricular morphology 
and measure wall thickness. 12-lead ECG and 24 hour ambulatory ECG monitoring 
was used to assess for T-wave inversion and non-sustained ventricular tachycardia 
(NSVT), respectively.  
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4. Results 
The mean age was 57.5 years old.  91 (72%) were male.  
44/126 (35%) genetic tests were informative. Patients with informative tests were 
younger, (median 50.2 years; inter-quartile range [IQR] 34.1-61.8) vs. 58.6 years; IQR 
50.0-66.5, p=0.007), were more likely to have a positive family history (FH) of HCM 
or sudden cardiac death (SCD) (59.1% vs 25.6%, p<0.001) and predominantly had 
reverse curve morphology of the interventricular septum (64%) (Figure 1.).  Twenty-
two (50%) patients had a variant in MYBPC3, 11(25%) in MYH7, 3(7%) in TNNI3. GLA, 
TNNT2, TPM1 had an incidence of 2. The incidence for CSRP3 and PRKAG was 1.  
Univariate analysis demonstrated that neither NSVT (p=0.29) or maximum measured 
wall thickness (p=0.70) predicted an informative test.  T wave inversion did not meet 
the generally accepted statistical cut-off p value of <0.05 (p=0.06). A lower 
proportion of patients with apical (18%) or sigmoid (19%) morphology had 
informative genetic testing, compared to 48% of those with reverse curve 
morphology.  
Multivariate analysis demonstrated that a reverse curve morphology (odds ratio 
(OR) 2.99, CI 1.28-7.01, p=0.012), family history of SCD/HCM (OR 2.91 CI 1.28-6.72, 
p=0.012) and younger age at time of testing (OR 0.97, CI 0.94-0.99, P=0.008) were 
predictive of an informative test. A family history of HCM/SCD and reverse curve 
morphology has a similar OR, 2.99 and 2.91 respectively, whereas younger age had 
less of an affect with an OR of 0.97. Although there were different OR weightings 
these 3 factors could then be used in a cumulative manner to predict informative 
tests. Age was converted from a continuous scale to a binary ≤50 or >50. If none of 
these factors were present the chance of finding an informative result was 10%. If 
one factor was present informative results were seen in 28%, 2 factors = 55% and all 
3 factors = 77%. 
 
Reverse curve morphology was the most common LV morphology seen with MYBPC3 
and MYH7 genetic mutations (77% of informative MYBPC3 tests and 60% of MYH7.) 
Apical, sigmoid, focal and concentric morphologies did not show any particular 
trends due to low numbers,  
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Reverse curve morphology accounted for a greater proportion of patients with 
informative results (28/44 (64%) patients), than in those with uninformative results 
(31/82 (38%) patients). It also highlights that more patients with uninformative 
results had apical or sigmoid morphologies. 24% and 27% of uninformative tests 
were apical and sigmoid in contrast to 11% for both apical and sigmoid in 
informative tests. 
 
 
5. Conclusions 
 
This data illustrates that younger age of diagnosis, FH of SCD or HCM and reverse 
curve morphology were positive predictors for informative genetic results. 
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Table 1: a) Univariate analysis showing the relationship between informative tests 
and phenotypic feature. b) Multivariate regression analysis using pre-defined clinical 
characteristics. c) The likelihood of informative test using a predictive model. 
 
Univariate analysis 
  Uninformative 
(n=82) 
Informative 
(n=44) 
P value 
Age at diagnosis 
(years) 
58.6 (50.0, 66.5) 50.2 (34.1, 61.8) 0.007 
FH SCD or HCM 21 (25.6) 26 (59.1) <0.001 
TWI 55 (67.1) 22 (50.0) 0.061 
NSVT 19 (23.2) 14 (31.8) 0.29 
Max width 18 (14, 21) 18 (14, 22) 0.70 
Morphology    
    Apical 23 (28.1) 5 (11.4) 0.032 
    Concentric 4 (4.9) 2 (4.6) >0.99 
    Focal 2 (2.4) 2 (4.6) 0.61 
    Reverse Curve 31 (37.8) 29 (65.9) 0.003 
    Sigmoid 21 (25.6) 5 (11.4) 0.060 
Multivariable logistic regression analysis 
 
 Odds Ratio 
(95% CI) 
P value 
Age at diagnosis 
(years) 
0.97 (0.94, 0.99) 0.008 
Family Hx of SCD or 
HCM 
2.91 (1.26, 6.72) 0.012 
Reverse Curve  2.99 (1.28, 7.01) 0.012 
Likelihood of informative gene test using predictive model 
Factors: Age <50, FH SCD/HCM, reverse curve septal morphology 
 
No. Factors Likelihood of positive result (%) 
3/3  77 
2/3  55 
1/3  28 
0/3  10 
